A Phase III, 12-week, Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Determine the Efficacy, Safety, and Tolerability of a Dose of 15 mg Bid of Evenamide as add-on in Patients With Documented Treatment-resistant Schizophrenia, Which is Not Adequately Controlled by a Stable Therapeutic Dose of the Patient's Current Antipsychotic Medication(s)

This is a prospective, 12-week, randomized, double-blind, placebo-controlled study, designed to evaluate the efficacy, safety, and tolerability of a dose of evenamide of 15 mg bid, compared to placebo, as add-on treatment in patients with documented treatment-resistant schizophrenia (TRS) who have prospectively demonstrated inadequate response to their current stable therapeutic dose of an antipsychotic(s). Approximately 400 patients will be randomized equally (1:1) to each of the two treatment groups in this study.

开始日期2026-01-23

申办/合作机构

Newron Pharmaceuticals SpA

CTIS2024-519836-18-00

/ Recruiting临床3期

A Phase III, 52-week, prospective, randomized, double-blind, placebo-controlled, parallel-group, multi-center study, with a primary efficacy endpoint at 12 weeks, to determine the efficacy, safety, and tolerability of fixed doses of 15 mg bid and 30 mg bid of evenamide as add-on in patients with documented treatment-resistant schizophrenia, which is not adequately controlled by a stable therapeutic dose of the patient’s current antipsychotic medication(s).

开始日期2025-12-16

申办/合作机构

Newron Pharmaceuticals SpA

SLCTR/2025/040

/ Suspended临床3期

开始日期2025-10-05

申办/合作机构

Newron Pharmaceuticals SpA

100 项与 Evenamide Hydrochloride 相关的临床结果

登录后查看更多信息

100 项与 Evenamide Hydrochloride 相关的转化医学

登录后查看更多信息

100 项与 Evenamide Hydrochloride 相关的专利（医药）

登录后查看更多信息

项与 Evenamide Hydrochloride 相关的文献（医药）

2026-04-01·EUROPEAN NEUROPSYCHOPHARMACOLOGY

Emerging neurobiological targets in psychiatric treatment

Review

作者: Berk, Michael ; Govinnage, Janani ; Giorlando, Frank ; De Zoysa, Agampodi Ishan ; Narayanaswamy, J C ; Dodd, Seetal

Despite significant advancements in psychopharmacology, there are inadequate treatment options for many psychiatric disorders, including major depressive disorder, bipolar disorder, schizophrenia, and anxiety disorders. This review explores emerging neurobiological targets beyond conventional monoaminergic approaches, focusing on sodium channels, Neuropeptide Y (NPY), Neurokinin 1 (NK1) receptors, P2 × 7 purinergic receptors, Sigma-1 receptors, and Orexin. Recent evidence suggests that sodium channel modulators, such as evenamide, may offer therapeutic benefits for treatment-resistant schizophrenia by stabilizing glutamatergic neurotransmission. NPY-based therapies have potential in stress-related disorders, foreshadowing rapid anxiolytic and antidepressant effects through modulation of the stress response. NK1 receptor antagonists, although inconsistent in mood disorders, show promise in addiction treatment by reducing substance cravings. The P2 × 7 receptor, a key regulator of neuroinflammation, has been implicated in mood disorders, and its pharmacological inhibition may provide neuroprotective benefits. Additionally, Sigma-1 receptor agonists, including Blarcamesine and Pridopidine, have shown neuroprotective and cognitive-enhancing properties, making them attractive candidates for psychiatric and neurodegenerative disorders. Orexin receptor antagonists, such as suvorexant and seltorexant, have potential in mood disorders and substance dependence, highlighting the broader therapeutic applications of targeting the orexinergic system. While these emerging therapeutic targets hold promise, challenges remain in translating preclinical findings into effective clinical applications. Large-scale, placebo-controlled trials are necessary to establish their efficacy and safety. The identification of biomarkers for patient stratification will be critical in the hitherto elusive goal of developing precision medicine approaches. Targeted pharmacological interventions offer a path toward more effective, well-tolerated, and potentially individualized treatment options for patients with severe mental illness.

2026-01-01·Therapeutic Advances in Psychopharmacology

Adjunctive treatment with evenamide, a glutamate modulator, is associated with clinically meaningful benefits in patients with treatment-resistant schizophrenia and inadequate response to antipsychotics: recent clinical findings from randomized trials

Article

作者: Roy, Arjun ; Hartman, Richard ; Sansi, Francesca ; Turolla, Alessio ; Anand, Ravi ; Chinellato, Giovanni

Background::

Despite their efficacy in improving positive symptoms, first- and second-generation antipsychotics (FGAs and SGAs) fail to provide benefit to a large portion of patients with schizophrenia. Evenamide, uniquely acting at the site of dysfunction, normalizes hippocampal glutamatergic aberrant activity and reduces downstream hyperdopaminergic state, potentially alleviating also negative and cognitive symptoms, and providing benefit to patients with treatment-resistant schizophrenia (TRS) or inadequate response to antipsychotics (APs).

Objectives::

Evaluate the clinical benefits of glutamate modulation through evenamide as an add-on treatment to FGAs and SGAs in patients with TRS or inadequate response to APs.

Design::

Post-hoc analyses of results from two phase II/III clinical trials with evenamide add-on to antipsychotic treatment.

Methods::

Data from Study 014/015, an open-label, 1-year trial in patients with TRS, was analyzed to assess the proportion of patients no longer meeting the baseline severity criteria for TRS (modified Intent-to-Treat (mITT) population; Observed Cases (OC)) and the proportion of patients in the mITT population achieving remission. Data from Study 008A, a randomized, double-blind, placebo-controlled, 4-week trial in patients with schizophrenia not adequately benefiting from SGA (including clozapine), was analyzed to assess patients’ response according to the number of previously failed AP attempts (ITT population; mixed model repeated measures (MMRM) linear regression model). The effect of evenamide on social functioning and life engagement was evaluated in both studies (mITT population) using an MMRM linear regression model for Study 008A and an OC analysis for Study 014/015.

Results::

Patients with TRS receiving evenamide add-on for 1-year improved to such an extent that 55% of them no longer satisfied baseline TRS severity criteria, and approximately one-fourth achieved remission according to literature criteria (27.6% Lieberman et al., 1993; 25.0% Andreasen et al., 2005). In Study 008A, irrespective of the number of failed APs, a statistically significant drug-placebo difference was observed in patients with a single failed attempt (−4.9, p = 0.0122) and in those with 2 or more failed attempts (−2.36, p = 0.0311). Moreover, add-on treatment with evenamide in Study 014/015 was associated with a progressive improvement on the PANSS subdomains of social functioning and life engagement. In Study 008A as well, evenamide resulted in a greater effect, compared to placebo, on the same subdomains.

Conclusion::

Add-on treatment with evenamide to APs (including clozapine) was associated with clinically meaningful and progressive long-term benefits across numerous post-hoc analyses including improvements on patient’s daily life and functioning.

2025-10-01·NEUROPSYCHOPHARMACOLOGY

Evenamide reverses schizophrenia-related dysfunction in a neurodevelopmental animal model

Article

作者: Rachel A. Walsh ; Anthony A. Grace ; Daniela L. Uliana ; Debora Fabris

Schizophrenia is characterized by positive, negative, and cognitive symptoms. However, current D2-based antipsychotic drugs only address primarily positive symptoms. Limbic hippocampus hyperexcitability is a key pathological state of schizophrenia, representing an ideal therapeutic target. Evenamide is a selective voltage-gated sodium channel blocker that reduces neuronal hyperexcitability. We examined the effect of acute evenamide treatment on the hyperdopaminergic state, hippocampal hyperexcitability, social deficits, and recognition memory in the methylazoxymethanol acetate (MAM) neurodevelopmental model. Male and female Sprague-Dawley offspring from dams treated with saline or MAM on gestational day 17 were tested as adults (postnatal day >65). Electrophysiological recordings were made in the ventral tegmental area (VTA) and ventral hippocampus (vHipp) and social approach and novel object recognition were tested. Evenamide (3 mg/kg i.p.) normalized the number of spontaneously active DA neurons in the VTA of female and male MAM rats and reduced pyramidal neuron hyperactivity in the vHipp. The hyperdopaminergic state in the VTA of female and male MAM rats was also rescued by local evenamide injection in the vHipp (1 µM). Systemic evenamide also reversed the recognition memory impairment of female and male MAM rats. For social deficits, only male MAM rats exhibit a reduced social sniffing time that was normalized by evenamide. These findings suggest that evenamide's efficacy in downregulating the hyperdopaminergic state, social deficits, and recognition memory impairment may result from its ability to attenuate vHipp hyperexcitability. Therefore, evenamide could offer a novel therapeutic strategy that is capable of addressing positive, cognitive, and negative symptoms of schizophrenia.

项与 Evenamide Hydrochloride 相关的新闻（医药）

2026-05-28

·Business Wire

Newron Pharmaceuticals to Participate in June Investor Conferences

MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)--Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), today announced that Stefan Weber, CEO and Roberto Galli, CFO, will participate in the following investor conferences in June: Newron Pharmaceuticals to participate in upcoming June investor conferences, including the Jefferies Global Healthcare Conference and H.C. Wainwright Neuro Perspectives Conference. Jefferies Global Healthcare Conference , June 2–4, 2026, New York H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference , June 15–16, 2026, Virtual At the Jefferies Global Healthcare Conference, members of the Newron management team will participate in a corporate presentation and one-on-one investor meetings. The corporate presentation will take place on Thursday, June 4, 2026, at 2:00 p.m. ET. At the H.C. Wainwright conference, members of the Newron team will participate virtually in a corporate presentation and one-on-one investor meetings. The pre-recorded corporate presentation will be available on-demand to registered conference attendees starting on June 15, 2026 at 7:00 A.M. (ET). To schedule a meeting with management during the conferences, please contact Casey Darby at cdarby@lavoiegroup.com. About Newron Pharmaceuticals Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on the development of innovative therapies for patients with diseases of the central and peripheral nervous system. Headquartered in Bresso, near Milan, Italy, the Company has a strong track record of advancing neuroscience-based treatments from discovery to market. Newron’s lead compound, evenamide, is a first-in-class glutamate modulator and has the potential to be the first add-on therapy for treatment-resistant schizophrenia (TRS) and for poorly responding patients with schizophrenia. Evenamide is currently developed in the global pivotal ENIGMA-TRS Phase III development program. Clinical trial results to date demonstrate the benefits of this drug candidate in the TRS as well as poorly responding patient population, with significant improvements across key efficacy measures increasing over time, as well as a favorable safety profile, which is uncommon for available antipsychotic medications. Newron has signed development and commercialization agreements for evenamide with EA Pharma (a subsidiary of Eisai) for Japan and other Asian territories, as well as Myung In Pharm for South Korea. Newron’s first marketed product, Xadago® (safinamide) has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland, the UK, the USA, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The product is commercialized by Newron’s partner, Zambon, with Supernus Pharmaceuticals holding marketing rights in the USA, and Meiji Seika responsible for development and commercialization in Japan and other key Asian territories. For more information, please visit: https://www.newron.com/ and connect with us on LinkedIn.

临床3期上市批准引进/卖出

2026-05-28

·BioSpace

Newron Pharmaceuticals to Participate in June 2026 Investor Conferences

MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)-- $NWRN #Biotech -- Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), today announced that Stefan Weber, CEO and Roberto Galli, CFO , will participate in the following investor conferences in June: Jefferies Global Healthcare Conference , June 2–4, 2026, New York H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference , June 15–16, 2026, Virtual At the Jefferies Global Healthcare Conference, members of the Newron management team will participate in a corporate presentation and one-on-one investor meetings. The corporate presentation will take place on Thursday, June 4, 2026, at 2:00 p.m. ET. At the H.C. Wainwright conference, members of the Newron team will participate virtually in a corporate presentation and one-on-one investor meetings. The pre-recorded corporate presentation will be available on-demand to registered conference attendees starting on June 15, 2026 at 7:00 A.M. (ET). To schedule a meeting with management during the conferences, please contact Casey Darby at cdarby@lavoiegroup.com . About Newron Pharmaceuticals Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on the development of innovative therapies for patients with diseases of the central and peripheral nervous system. Headquartered in Bresso, near Milan, Italy, the Company has a strong track record of advancing neuroscience-based treatments from discovery to market. Newron’s lead compound, evenamide, is a first-in-class glutamate modulator and has the potential to be the first add-on therapy for treatment-resistant schizophrenia (TRS) and for poorly responding patients with schizophrenia. Evenamide is currently developed in the global pivotal ENIGMA-TRS Phase III development program. Clinical trial results to date demonstrate the benefits of this drug candidate in the TRS as well as poorly responding patient population, with significant improvements across key efficacy measures increasing over time, as well as a favorable safety profile, which is uncommon for available antipsychotic medications. Newron has signed development and commercialization agreements for evenamide with EA Pharma (a subsidiary of Eisai) for Japan and other Asian territories, as well as Myung In Pharm for South Korea. Newron’s first marketed product, Xadago® (safinamide) has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland, the UK, the USA, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The product is commercialized by Newron’s partner, Zambon, with Supernus Pharmaceuticals holding marketing rights in the USA, and Meiji Seika responsible for development and commercialization in Japan and other key Asian territories. For more information, please visit: and connect with us on LinkedIn . Contacts Newron Stefan Weber – CEO +39 02 6103 46 26 pr@newron.com UK/Europa Simon Conway / Ciara Martin / Natalie Garland-Collins, FTI Consulting +44 20 3727 1000 SCnewron@fticonsulting.com Switzerland Valentin Handschin, IRF +41 43 244 81 54 handschin@irf-reputation.ch Germany/Europa Anne Hennecke / Maximilian Schur, MC Services +49 211 52925227 newron@mc-services.eu USA Casey Darby, LaVoieHealthScience +1 617 351 0244 cdarby@lavoiegroup.com

临床3期上市批准

2026-05-14

·瀚枢生物Kylinlab

精神分裂症新药研发接连受挫，破局之路在何方？

近期，精神分裂症药物研发领域连续遭遇两起挫折：Alto Neuroscience的ALTO-101在治疗认知障碍的Ⅱ期试验中未达主要终点；Newron的 evenamideⅢ期试验中一例患者死亡，尽管经评估该事件与药物无关，仍被FDA叫停。类似事件在精神疾病药物的研发中不在少数，但庞大的临床缺口与市场潜力，驱动着行业不断前进。精神分裂症破局新方向回顾过去近70年的治疗史，几乎所有精神分裂症药物都走着同一条路——阻断多巴胺D2受体。这一方法能缓解幻觉、妄想等“阳性症状”，但对社会退缩、快感缺失等“阴性症状”和认知功能损害效果有限，许多患者虽不再出现急性精神病性发作，却长期处于功能严重受损的状态，生活质量难以改善。问题的根源在于：精神分裂症不是单一病因的疾病，仅凭某一药物不太可能有效治疗精神分裂症的所有症状。目前的研究已经揭示，患者大脑皮层存在突触连接减少、树突棘密度下降，抑制性GABA能神经元功能减退；超过200个相关风险基因位点被锁定，多数参与突触结构、神经发育或髓鞘形成，而谷氨酸能相关基因的富集程度远超多巴胺系统。基于对疾病机制的深入研究，精神分裂症的治疗正迎来新的转机。精神分裂症患者皮层神经病理学与皮层下多巴胺能功能障碍之间的脑回路聚焦谷氨酸能信号通路谷氨酸是大脑最主要的兴奋性神经递质，参与约80%的皮层‑边缘系统突触活动。研究证实，NMDAR（N-甲基-D-天冬氨酸离子型谷氨酸受体）功能不足是疾病的关键病理机制之一。围绕这一靶点，多条策略正在加速推进：抑制GlyT1：提高突触间隙甘氨酸浓度，增强NMDAR信号。代表药物：勃林格殷格翰的iclepertin（BI425809），已进入Ⅲ期临床，用于治疗精神分裂症相关认知障碍。抑制KATII：减少内源性NMDAR拮抗物犬尿氨酸的生成，例如Kynexis的KYN-5356，处于Ⅱ期临床。其他策略：调节神经元兴奋性、减少异常谷氨酸释放，或促进突触再生与神经网络重塑。这些尝试不再局限于“控制症状”，而是试图修复大脑的兴奋性信号失衡，为认知和阴性症状的改善带来真正的希望。胆碱能信号通路：新机制突破除谷氨酸能通路外，胆碱能信号通路为精神分裂症的治疗开辟了另一条路径。其中，mAChR（毒蕈碱型乙酰胆碱受体）药物已显现出良好的抗精神病活性，尤其是靶向M1/M4型mAChR的药物，有望治疗精神分裂症核心症状。由BMS与再鼎医药联合研发的KarXT，作为一种M1/M4型mAChR激动剂和mAChR拮抗剂的组合药物，能够改善阳性和阴性症状，同时规避传统药物的部分风险。该药于2024年9月获FDA批准上市，并于2025年12月在我国上市，KarXT也是近几十年来首款不依赖多巴胺D2受体机制的新型抗精神病药物。 Maplight的M1/M4型mAChR激动剂/拮抗剂组合药物ML-007C-MA已进入Ⅱ期临床。瀚枢生物助力纽欧申医药临床转化的NS-136作为国内首款新型选择性M4型mAChR正向变构调节剂，也已处于Ⅱ期临床试验阶段。还有多项相关研究已推进至临床，可见靶向毒蕈碱受体的神经精神类新药研发，已成为行业热门方向。相关阅读：解码毒蕈碱受体，驱动神经精神新药研发其他新兴靶点并进神经可塑性：sGC（可溶性鸟苷酸环化酶）刺激剂、PDE9（磷酸二酯酶9）抑制剂等通过提高细胞内cGMP（环鸟苷酸）水平增强突触可塑性，改善认知症状。 TAAR1激动剂：TAAR1（微量胺相关受体1）是目前最受关注的靶点之一。大冢制药的ulotaront（SEP-363856）已进入Ⅲ期临床，能在不阻断D2受体的前提下同时改善阳性与阴性症状。炎症与代谢：炎症反应、氧化应激及代谢异常也逐渐成为研究热点，相关辅助治疗有助于改善患者整体健康、降低共病风险。部分在研精神分裂症药物精神分裂症药物研发是一场漫长探索。随着病理机制的进一步阐明，谷氨酸能、胆碱能、TAAR1等多条通路正齐头并进，未来有望诞生更多创新药物，填补治疗空白。瀚枢生物助力精神分裂症相关药物研发瀚枢生物专注于提供CNS药物研发临床前CRO服务，目前已建立了全面的CNS药物研究平台。参与过众多精神分裂症药物临床前研发项目，积累了丰富的经验。已拥有全面的经充分验证的疾病模型，化学药物诱导的各类精神分裂症样动物模型，能够模拟出精神分裂症阳性症状、阴性症状以及认知功能损害等核心临床表现；并搭建了多维度的药物药效评价体系，包括行为学评价、生物标志物检测、电生理等。可为精神分裂症药物研发提供全流程、高适配性的一体化技术解决方案，有效提升药物的临床转化率。参考资料： Joseph T. Coyle, Steven M. Paul.Novel drug treatments for schizophrenia. Nature Reviews Drug Discovery volume 25, pages310–330 (2026) https://mp.weixin.qq.com/s/D9BPx1N1hnm7j6RNjC-Cjw?scene=1 https://mp.weixin.qq.com/s/gxXF4NGvYa5jhAefrhFiJA?scene=1 瀚枢生物 CNSxplore | 提供一站式神经系统药物研发解决方案上海瀚枢生物是专注于中枢神经系统（CNS）疾病的临床前CRO公司，致力于为CNS药物研发提供一体化解决方案。拥有充分验证的细胞和动物疾病模型，结合全面的研究与分析能力，助力客户加速创新疗法开发，降低临床失败风险。瀚枢生物具有经验丰富、熟悉中外法规的技术团队和高标准实验平台，核心技术涵盖AI驱动表型筛选、人源化干细胞与类器官、电生理、高通量脑电图（EEG）、组织学和分子生物学，覆盖阿尔茨海默病、帕金森病、抑郁症、精神分裂症、SMA、疼痛与卒中等领域。自成立以来，瀚枢生物始终秉持“研发率先、技术领先、质量优先、客户至上”的理念，已服务百余家客户，成功完成多项专题研究与IND申报，建立了高质量、稳定且具前瞻性的药效评价体系。电话 | 021-50882331 地址 | 上海市浦东新区张江科学城秀浦路2555号A1座10层

100 项与 Evenamide Hydrochloride 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	Evenamide Hydrochloride	-	-

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
精神分裂症，难治性	临床3期	阿根廷	Newron Pharmaceuticals SpA	2025-12-16
精神分裂症，难治性	临床3期	巴西	Newron Pharmaceuticals SpA	2025-12-16
精神分裂症，难治性	临床3期	保加利亚	Newron Pharmaceuticals SpA	2025-12-16
精神分裂症，难治性	临床3期	加拿大	Newron Pharmaceuticals SpA	2025-12-16
精神分裂症，难治性	临床3期	哥伦比亚	Newron Pharmaceuticals SpA	2025-12-16
精神分裂症，难治性	临床3期	克罗地亚	Newron Pharmaceuticals SpA	2025-12-16
精神分裂症，难治性	临床3期	捷克	Newron Pharmaceuticals SpA	2025-12-16
精神分裂症，难治性	临床3期	法国	Newron Pharmaceuticals SpA	2025-12-16
精神分裂症，难治性	临床3期	德国	Newron Pharmaceuticals SpA	2025-12-16
精神分裂症，难治性	临床3期	匈牙利	Newron Pharmaceuticals SpA	2025-12-16

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


EUCTR2020-006062-36-CZ (008A, Pubmed \| NEWS 1 \| NEWS 2)	临床2/3期	精神分裂症	291	Evenamide	襯壓夢衊築膚糧鏇願糧(蓋窪選製鬱襯獵壓淵憲) = 窪築憲夢壓襯壓窪築餘積廠簾遞壓繭夢糧膚鹽 (觸製繭糧觸淵襯廠齋鬱 ) 更多	积极	2024-04-30
EUCTR2020-006062-36-CZ (008A, Pubmed \| NEWS 1 \| NEWS 2)	临床2/3期	精神分裂症	291	安慰剂	襯壓夢衊築膚糧鏇願糧(蓋窪選製鬱襯獵壓淵憲) = 蓋鬱鹹構遞鹽夢衊艱觸積廠簾遞壓繭夢糧膚鹽 (觸製繭糧觸淵襯廠齋鬱 ) 更多	积极	2024-04-30
EUCTR2020-000437-41-IT (Study 015, Biospace) 人工标引	N/A	精神分裂症，难治性	121	Evenamide	窪蓋鹽繭鹽齋壓壓鑰鹽(製壓鏇淵艱齋夢鹹範衊) = 選願製簾鑰艱衊積鏇壓範顧糧齋糧製觸選鏇觸 (夢遞窪鹽餘觸獵觸膚廠 ) 更多	积极	2024-01-04
Study 015 (Corporate Publications) 人工标引	临床2期	精神分裂症，难治性	97	Evenamide	糧鬱鑰構衊選範獵衊憲(構餘顧積鏇積壓築鹹顧) = 願鑰獵膚鹽簾淵鏇夢簾衊鏇醖醖窪蓋齋鬱觸網 (顧衊廠構選網衊餘製襯 ) 更多	积极	2023-05-07
CTRI/2020/09/027537 (Corporate Publications) 人工标引	临床2期	精神分裂症，难治性	161	Evenamide	鏇蓋蓋壓簾餘憲鬱蓋構(衊觸鏇衊鏇鏇願鏇鹽製) = The mean Positive and Negative Syndrome Scale (PANSS) total score, Clinical Global Impression of Severity (CGI-S) rating, and the Strauss-Carpenter Level of Functioning (LOF) total score significantly improved compared to baseline (p<0.001). 艱觸淵鹽觸糧餘製鹹淵 (觸獵獵糧窪夢鑰鑰願鑰 ) 更多	积极	2023-03-20
CTRI/2020/09/027537 (Corporate Publications) 人工标引	临床2期	精神分裂症，难治性	100	evenamide	窪願糧繭窪築築窪衊淵(遞網鬱積壓築壓蓋鹽觸) = The proportion of patients experiencing clinically meaningful improvement (i.e., patients rated at least “much improved”) on the Clinical Global Impression of Change (CGI-C) increased by an additional 10% at one year from the proportion at week six (27%). 膚淵鹹構醖鹽餘網獵構 (蓋襯選鏇蓋繭簾壓繭鑰 ) 更多	积极	2023-02-16
Corporate Publications 人工标引	N/A	精神分裂症，难治性	100	evenamide	積獵積範顧鏇餘簾窪選(衊遞獵餘糧鑰觸蓋網鑰) = 鏇醖壓築選艱鑰憲襯襯淵網憲壓簾憲淵壓蓋廠 (窪鹽齋艱願鬱艱製憲遞 ) 更多	积极	2022-06-07
NCT01955564 (CTgov)	临床1期	精神分裂症	54	NW-3509a (Cohort 1)	壓構繭衊製鬱鹹積積簾 = 憲選鑰鹽構鏇膚顧積選蓋淵願窪窪襯夢鬱網網 (鹽窪積艱簾獵鹹鏇艱獵, 觸夢膚觸顧醖鬱艱遞鏇 ~ 鏇壓夢鏇選鹹蓋餘衊齋) 更多	-	2017-06-20
NCT01955564 (CTgov)	临床1期	精神分裂症	54	NW-3509a (Cohort 2)	壓構繭衊製鬱鹹積積簾 = 獵簾艱餘觸蓋廠憲窪製蓋淵願窪窪襯夢鬱網網 (鹽窪積艱簾獵鹹鏇艱獵, 積遞積遞積壓遞築顧糧 ~ 憲艱繭襯製窪淵繭鹹獵) 更多	-	2017-06-20